Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.BioPontis Alliance has entered into a strategic agreement with Merck (known outside the US and Canada as MSD) designed to bridge the gap between early academic discovery science and the development of medicines and technologies that impact human health.
Subscribe to our email newsletter
As per the agreement, Merck will provide BioPontis Alliance with guidance on Merck product portfolio priorities, thereby ensuring alignment of market demand with the discovery science that BioPontis Alliance will invest in.
Additionally, Merck will also provide BioPontis Alliance with scientific and medical counsel on product development strategy, design of experiments, selection of technical development tools and resources, and final development milestone objectives.
The agreement provides Merck with informed access to license evaluated therapeutic technologies.
Merck Worldwide Licensing and Knowledge Management senior vice president and head David Nicholson said that they look forward to working with BioPontis Alliance’s scientific managers to apply their translational medicine expertise in expediting the advancement of early drug candidates and technologies with a focus on improving the lives of the patients that need them.